CytoDyn Motivated by Disappointing Results for Big Pharma's Bird Flu Vaccine

SANTA FE, N.M.--(BUSINESS WIRE)--CytoDyn, Inc. (Pink Sheets:CYDY) sees a new reason to expedite development of its DNA-based pre-flu vaccine: a report that the first vaccine for the bird flu is even less effective than first believed. Documents released by the FDA on February 26, 2007 report that the vaccine manufactured by Sanofi-Aventis (NYSE: SNY) protects only 45% of vaccinated adults against the bird flu, according to a widely reported story by the Associated Press. See e.g., www.foxnews.com/story/0,2933,254722,00.html. An interim report appearing in the March 2006 issue of the New England Journal of Medicine, vol. 354, pages 343-351, suggested that 54% of those vaccinated might be protected.